Clinical Trial Update: A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating MBG453 in combination with azacitidine and venetoclax in AML patients unfit for chemotherapy has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• MBG453
• Venetoclax (venetoclax)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2025-11-17